Targeted treatment for HER2-positive breast cancer with brain metastases
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new treatment (a theranostic agent) that combines imaging and therapy to target cancer cells in the brain. It is for people with HER2-positive breast cancer that has spread to the brain, and may help by delivering radiation directly to the tumor while minimizing harm to healthy tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have HER2-positive breast cancer (a type of breast cancer that has too much of a protein called HER2).
- You must have brain metastases that are either new or have grown after previous treatment. You can have any number of brain lesions.
- You must have at least one brain lesion that can be measured on an MRI (at least 10 mm in size).
- Your corticosteroid (steroid) dose must be stable or lower, or you must not be taking steroids, for at least 7 days before starting the study.
- You must be able to take care of yourself (up to bedridden less than 50% of the time) and have a life expectancy of at least 6 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted cancer drug (T-DXd) with precise radiation to the brain for people with HER2-positive breast cancer that has spread to the brain. It aims to see if this combination can better control the brain tumors while being safe.
This trial tests a special PET/MRI imaging scan using a labeled drug to help doctors evaluate HER2+ breast cancer that has spread to the brain. It focuses on patients who plan to receive fam-trastuzumab deruxtecan, a targeted cancer medicine, and aims to see how well the scan can support treatment decisions.
This study is testing a new targeted therapy for people with HER2-positive breast cancer that has spread to the brain. It aims to see if the drug can help shrink brain tumors and improve outcomes for two groups: those with cancer in the fluid around the brain and those without.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
This trial tests a combination of a targeted drug called sacituzumab govitecan (Trodelvy) with radiation to the head for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this combination can shrink brain tumors and improve outcomes.
This trial tests two new drugs, SHR-A1811 and THPy, for women with HER2-positive advanced breast cancer that has spread to the brain. It aims to see if this combination can shrink brain tumors and improve outcomes for patients who have not yet had systemic treatment for advanced disease.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.